FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website
horizonal rule
Dockets Management


C 38
Volume 152


Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proceedings of the National Academy of Sciences 1993; 90: 2291-4. Published Material

Brachman PS, Friedlander AM, Grabenstein JD. Chapter 31: Anthrax. In: Plotkin SA, Orenstein WA, ed. Vaccines, 4th ed. Philadelphia: Elsevier, 2003: 887-903. Published Material

Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingram NR. Field evaluation of human anthrax vaccine. American Journal of Public Health 1962; 52: 632-45. www.anthrax.mil/media/pdf/field_eval.pdf Published Material

Guarner J, Jernigan JA, Shieh W-J, Tatti K, Flannagan LM, Stephens DS, Popovic T, Ashford DA, Perkins BA, Zaki SR, Inhalational Anthrax Pathology Working Group. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. American Journal of Pathology 2003; 163: 701-9. Published Material

Johnson-Winegar A. Comparison of enzyme-linked immunosorbent and indirect hemagglutination assays for determining anthrax antibodies. Journal of Clinical Microbiology 1984; 20: 357-61. Published Material

Lincoln RE, Fish DC. Anthrax toxin. In: Montie TC, Kadis S, Ajl SI, eds. Microbial Toxins, Volume III, Bacterial Protein Toxins. New York: Academic Press: 1970 :361-414. Published Material

Lincoln RE, Hodges DR, Klein F, Mahlandt BG, Jones WL Jr., Haines BW, Rhian MA, Walker JS. Role of the lymphatics in the pathogenesis of anthrax. Journal of Infectious Disease 1965;115: 481-94. Published Material

Pittman PR, Mangiafico JA, Rossi CA, Cannon TL, Gibbs PH, Parker GW, Friedlander AM. Anthrax vaccine: Increasing intervals between the first two doses enhances antibody response in humans. Vaccine 2000; 18:213-216. Published Material

Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, Pace-Templeton JG, Myers R, Parker GW, Friedlander AM. Anthrax vaccine: Immunogenicity and safety of a dose-reduction, route comparison study in humans. Vaccine 2002 (Jan 31); 20: 1412-20. http://www.vaccines.mil/documents/library/Immunoogenicity.pdf Published Material

Shieh W-J, Guarner J, Paddock C, Greer P, Tatti K, Fischer M, Layton M, Philips M, Bresnitz E, Quinn CP, Popovic T, Perkins BA, Zaki SR, Anthrax Bioterrorism Investigation Team. The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax. American Journal of Pathology 2003; 163: 1901-10. Published Material

Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Archives of Pathology and Laboratory Medicine 1998; 122: 982-92. Published Material

Top | Back

Page last updated July 27, 2005 RSChorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management